Alterations involving the KMT2A gene, formerly known as MLL, are detected in around 5% of childhood ALL, with a higher prevalence among infants; these genetic rearrangements are strongly associated with more aggressive disease and adverse clinical outcomes [20]. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.